Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Invests In Deals, Share Buybacks And Manufacturing As Sales Dip

Feb 02 2018

• By Mandy Jackson

Business decline

Related Content

First Biosimilar Neulasta In Final Stages Of EMA Review Process

Dec 15 2017

Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA

Oct 10 2017

Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha

Dec 02 2017

Parsabiv Could Allow Amgen To Maintain Control Of Calcimimetics Market

Feb 20 2017

Mylan Insists Complex Generics Strategy Is Poised To Deliver

Nov 06 2017

Amgen Hit By Enbrel 'Peculiarities' And Repatha Resistance

Apr 27 2017

Erenumab Moves Ahead In Treatment-Refractory Migraine in Novartis/Amgen LIBERTY Study

Jan 23 2018

Related Companies

Amgen, Inc.

Viatris Inc.

Additional Topics

Sales & Earnings Deals Business Strategies Companies Commercial BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window